Assessment of Pattern of CD4+ T-Cell Recovery Among Human Immunodeficiency Virus Patients After Initiation of Highly Active Antiretroviral Therapy at Arsi Negelle Health Center, Ethiopia: A Retrospective Cross-Sectional Study

• Published in: HIV/AIDS (Auckland) Vol. 12; pp. 69 - 77
• Main Authors: Barasa Gelba, Sileshi, Fikadu, Surafel, Kindie Legesse, Alemawi, Wubet, Hiwot, Alemu Yesuf, Mihret, Abera, Wondwossen, Bizuayehu Wube, Temesgen
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2020; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: Acquired immune deficiency syndrome; Age; AIDS; Analysis; Antiretroviral agents; Antiretroviral drugs; arsi negelle; Care and treatment; CD4 antigen; cd4+ t-cell recovery; Children; Complications and side effects; Cross-sectional studies; Data collection; Drug therapy; Efavirenz; ethiopia; Highly active antiretroviral therapy; HIV; HIV patients; Human immunodeficiency virus; immunological none-response rate; Immunology; Information storage and retrieval; Lymphocytes; Lymphocytes T; Medical records; Medical research; Mortality; Original Research; Recovery (Medical); Regression analysis; Sociodemographics; T cells; Trends; Ethiopia; CD4+ T-cell recovery; immunological non-response rate; Arsi Negelle; Ethiopia
• DOI: 10.2147/HIV.S229036
• ISSN: 1179-1373

Antiretroviral therapy has resulted in significant reductions in HIV-associated complications by recovering the CD4+ T cell count. Some patients may not be successful in attaining this result, and some may achieve it only after many years of treatment. This study aimed to assess CD4+ T cell recovery and non-response patterns among HAART experienced HIV-positive patients at the Arsi Negelle health center. This was a retrospective cross-sectional study conducted among HAART experienced HIV/AIDS patients at Arsi Negelle Health Center from January 01, 2014 to January 06, 2019. Data were documented to a data retrieval form and analyzed with SPSS version 20. Linear regression analysis was used to identify predictors of CD4 count change. A P-value of <0.05 was considered significant. The total median of CD4+ T cells increased from 257 cells/uL at the baseline to 382 cells/uL after 6 months, then to 591 cells/uL after 60 months of treatment. The non-response rate was 22.1% and 23.8% among the total study participants and children of less than 15 years, respectively. Only baseline CD4+ T cell was associated with a change in CD4+ T cell count. From our study, we can conclude that CD4+ T cell count has recovered in most of the study participants after HAART initiation. The immunological non-response rate of study participants was 22.1% after 12 months on HAART and 7.2% at the end of the study.